| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Capsaicin is a chemical compound that gives chili peppers their spicy flavor and heat. Biological activity, capsaicin has been reported to exhibit a range of effects, including: Pain relief: 10-50 μM Anti-inflammatory activity: 20-50 μM Antioxidant activity: 10-100 μM Anti-cancer activity: 50-100 μM Cardiovascular health: 20-50 μM Approximate μM concentrations of capsaicin, the active compound in chili peppers, that can be achieved with different amounts of chili peppers: 1 teaspoon of dried chili pepper flakes (5g):~10-50 μM of capsaicin 1 tablespoon of dried chili pepper flakes (15g): ~30-150 μM of capsaicin 1 cup of fresh chili peppers (100g): ~100-500 μM of capsaicin 1 teaspoon of chili pepper extract (5g): ~100-500 μM of capsaicin 1 tablespoon of chili pepper extract (15g): ~300-1500 μM of capsaicin Approximate μM concentrations of capsaicin in various foods that contain capsaicin: Jalapeño peppers: 1 pepper (20g): ~20-100 μM of capsaicin 2–8 mg/100g of fresh Jalapeño Serrano peppers: 1 pepper (10g): ~10-50 μM of capsaicin 5–15 mg/100g Cayenne peppers: 1 pepper (10g): ~50-200 μM of capsaicin Habanero peppers: 1 pepper (20g): ~100-500 μM of capsaicin 15–30 mg/100g Ghost peppers: 1 pepper (20g): ~200-1000 μM of capsaicin Hot sauce: 1 teaspoon (5g): ~10-50 μM of capsaicin Chili flakes: 1 teaspoon (5g): ~10-50 μM of capsaicin Spicy sauces and marinades: 1 tablespoon (15g): ~10-50 μM of capsaicin Cayenne Pepper Powder – Approximate capsaicin content: roughly 5–20 mg/g (15-30g human for 100uM?) -IC50 in Cancer Cell Lines: Approximately 50–300 µM (consume 150mg of capsaican not possible?) -IC50 in Normal Cell Lines: Generally higher—often 2–3 times greater Pathways: -disrupting mitochondrial membrane potential, leading to cytochrome c release and subsequent activation of caspases -Activation of TRPV1: resulting in increased intracellular calcium levels -capsaicin can lead to increased production of ROS within cancer cells -Inhibition of NF-κB -Inhibit PI3K/AKT/mTOR signaling -STAT3 Inhibition -Cell Cycle Arrest -reduce the expression of vascular endothelial growth factor (VEGF) -COX-2 -capsaicin is a natural ADAM10 activator and shows potential to attenuate amyloid pathology and protect against AD Capsaicin — capsaicin is a pungent vanilloid alkaloid phytochemical from Capsicum peppers and the principal TRPV1 agonist responsible for chili heat. It is best classified as a natural product / small-molecule vanilloid with approved topical analgesic use but no established anticancer indication. Standard abbreviations include CAP and CAPS. In cancer literature it is a pleiotropic stressor whose dominant preclinical effects usually converge on Ca2+ influx, mitochondrial dysfunction, ROS generation, suppression of pro-survival signaling, and apoptosis, but its biology is context- and concentration-dependent, with occasional low-dose pro-migratory / pro-metastatic signaling reported. Primary mechanisms (ranked):
Bioavailability / PK relevance: Capsaicin is lipophilic, rapidly absorbed, and rapidly metabolized, with substantial first-pass limitation after oral exposure. Human oral PK from a capsicum preparation containing 26.6 mg capsaicin produced a Cmax of about 2.47 ng/mL at ~47 minutes, while the FDA-approved 8% topical system produced transient systemic exposure usually below 5 ng/mL, with a highest detected plasma level of 4.6 ng/mL. Delivery is therefore a major translation constraint for anticancer use, and formulation-based approaches are often invoked to overcome short half-life, irritancy, and exposure limits. In-vitro vs systemic exposure relevance: This is a major limitation. Many anticancer cell studies use roughly 10–300 µM, whereas reported human plasma exposures from oral or approved topical use are in the low ng/mL range, approximately ~0.008–0.015 µM, i.e., orders of magnitude lower than many cytotoxic in-vitro concentrations. Accordingly, direct systemic tumoricidal translation from standard dietary or approved topical exposure is weak unless local delivery, sustained-release systems, or substantially altered formulations are used. Clinical evidence status: Anticancer evidence is predominantly preclinical, with in-vitro and some in-vivo support across several tumor types. There is no regulatory approval for cancer treatment. Human oncology use is currently much more credible as supportive care for neuropathic pain, especially chemotherapy-induced peripheral neuropathy, where topical high-concentration capsaicin patches are being studied and used off-label / investigationally, rather than as a direct antitumor therapy. Mechanistic Table
P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: |
| Type: |
| TRPV1 is a ligand-gated ion channel classically associated with nociception and heat sensation. - TRPV1 is a nonselective cation channel that allows the influx of calcium (and other cations) when activated by various stimuli such as capsaicin, heat, or low pH. - TRPV1 can influence key cellular processes including proliferation, apoptosis, and migration by modulating intracellular calcium levels and downstream signaling cascades. - In some cases, TRPV1 activation can induce cell death, which might translate into less aggressive tumor behavior; however, this is not a universal finding. - TRPV1 is a non-selective cation channel, which is frequently overexpressed in highly malignant cancers. - Capsaicin may be able to induce cell death in urothelial cancer and glioma cells via TRPV1-dependent stimulation of excessive calcium (Ca2+) influx - Activation of TRPV1 promotsd the generation of ROS. - Variability in TRPV1 expression and function suggests that it might serve as one component of a broader prognostic panel rather than a standalone marker. |
| 5842- | CAP, | Capsaicin: Current Understanding of Its Mechanisms and Therapy of Pain and Other Pre-Clinical and Clinical Uses |
| - | Review, | Nor, | NA | - | Review, | Diabetic, | NA |
| 5839- | CAP, | Capsaicin: beyond TRPV1 |
| - | Review, | Var, | NA |
| 5834- | CAP, | Capsaicin and TRPV1: A Novel Therapeutic Approach to Mitigate Vascular Aging |
| - | Study, | Nor, | NA |
| 5831- | CAP, | Unraveling TRPV1’s Role in Cancer: Expression, Modulation, and Therapeutic Opportunities with Capsaicin |
| 5830- | CAP, | Inhibition of pyroptosis and apoptosis by capsaicin protects against LPS-induced acute kidney injury through TRPV1/UCP2 axis in vitro |
| - | in-vitro, | Nor, | HK-2 |
| 5827- | CAP, | The Effect of Topical Capsaicin 8% on Pain in Chemotherapy-induced Peripheral Neuropathy |
| - | Trial, | Var, | NA |
| 5826- | CAP, | Capsaicin induces mitochondrial dysfunction and apoptosis in anaplastic thyroid carcinoma cells via TRPV1-mediated mitochondrial calcium overload |
| - | in-vitro, | Thyroid, | NA |
| 5825- | CAP, | Bioavailability of capsaicin and its implications for drug delivery |
| - | Review, | Var, | NA | - | Review, | Arthritis, | NA | - | Review, | Obesity, | NA |
| 5861- | CAP, | Anticancer Properties of Capsaicin Against Human Cancer |
| - | Review, | Var, | NA |
| 5860- | CAP, | Beneficial Effects of Capsaicin in Disorders of the Central Nervous System |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 5859- | CAP, | Are We Ready to Recommend Capsaicin for Disorders Other Than Neuropathic Pain? |
| - | Review, | Var, | NA |
| 5858- | CAP, | Capsaicin as a Microbiome Modulator: Metabolic Interactions and Implications for Host Health |
| - | Review, | Nor, | NA | - | Review, | AD, | NA |
| 5855- | CAP, | Unravelling the Mystery of Capsaicin: A Tool to Understand and Treat Pain |
| - | in-vivo, | Nor, | NA |
| 5854- | CAP, | Pharmacological activity of capsaicin: Mechanisms and controversies (Review) |
| - | Review, | Var, | NA | - | Review, | AD, | NA |
| 5850- | CAP, | Anticancer Activity of Natural and Synthetic Capsaicin Analogs |
| - | Review, | Var, | NA |
| 5849- | CAP, | The Impact of TRPV1 on Cancer Pathogenesis and Therapy: A Systematic Review |
| - | Review, | Var, | NA |
| 5845- | CAP, | Unveiling the Molecular Mechanisms Driving the Capsaicin-Induced Immunomodulatory Effects on PD-L1 Expression in Bladder and Renal Cancer Cell Lines |
| - | in-vivo, | RCC, | A498 | - | in-vitro, | RCC, | T24/HTB-9 | - | NA, | Bladder, | 5637 |
| 5844- | CAP, | Non-pungent long chain capsaicin-analogs arvanil and olvanil display better anti-invasive activity than capsaicin in human small cell lung cancers |
| - | in-vitro, | Lung, | DMS114 |
| 2019- | CAP, | Capsaicin: A Two-Decade Systematic Review of Global Research Output and Recent Advances Against Human Cancer |
| - | Review, | Var, | NA |
| 2018- | CAP, | MF, | Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma |
| - | Review, | HCC, | NA |
| 2012- | CAP, | Capsaicin induces cytotoxicity in human osteosarcoma MG63 cells through TRPV1-dependent and -independent pathways |
| - | NA, | OS, | MG63 |
| 5202- | CAP, | Capsaicin Suppresses Cell Proliferation, Induces Cell Cycle Arrest and ROS Production in Bladder Cancer Cells through FOXO3a-Mediated Pathways |
| - | vitro+vivo, | Bladder, | 5637 | - | in-vitro, | Bladder, | T24/HTB-9 |
| 2349- | CAP, | The TRPV1-PKM2-SREBP1 axis maintains microglial lipid homeostasis in Alzheimer’s disease |
| - | in-vivo, | AD, | NA |
| 2020- | CAP, | Capsaicinoids and Their Effects on Cancer: The “Double-Edged Sword” Postulate from the Molecular Scale |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:55 Target#:1227 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid